瑞泰新材 reported revenue of ¥1.46B for the period ended 2026-06-30, +49.8% year on year. Net income was ¥0.19B, a 12.9% net margin on a 13.0% gross margin. The largest revenue line is 电子化学品 at 96% of the total. Free cash flow for the period was ¥-0.12B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.46B | +49.8% |
| Gross profit | ¥0.19B | — |
| Operating income | ¥0.24B | — |
| Net income | ¥0.19B | +100.6% |
| Gross margin | 13.0% | Net margin 12.9% |
| Revenue Q/Q | +15.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| 电子化学品 | ¥1.41B | 96.3% |
| 其他主营业务 | ¥0.05B | 3.3% |
| 其他(补充) | ¥0.01B | 0.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.27B | 87.0% |
| R&D | ¥0.04B | 2.7% |
| SG&A | ¥0.07B | 5.1% |
| Tax & other | ¥0.05B | 3.5% |
| Item | Amount |
|---|---|
| Total assets | ¥9.42B |
| Total liabilities | ¥2.05B |
| Shareholders' equity | ¥7.37B |
| Equity / assets | 78.2% |
| Operating cash flow | ¥-0.11B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥-0.12B |
| Cash conversion (OCF / net income) | -138% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
普瑞眼科 ・ 宏源药业 ・ 杰创智能 ・ 威尔高 ・ 同星科技 ・ 通力科技 ・ 华融化学 ・ 普蕊斯 ・ 富士莱 ・ 艾布鲁 ・ 格力博 ・ 恒工精密
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies